CClinicalTrials.gg
Sign In
Status unknownNCT03291275Updated Feb 8, 2018

Survival Outcomes of Uterine Malignancies in Chinese Population

An observational study in Endometrial Neoplasms and Survival, sponsored by Lei Li. Status unknown at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2018-02-08.

Sponsored by Lei Li · Observational

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Sex
Female
01

Study summary

This study aims to determine survival outcomes (overall survival and progression-free survival) of primary uterine malignancies in China and relevant risk factors in a prospective cohort study.

02

Conditions studied

  • Endometrial Neoplasms
  • Survival
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with definite diagnosis of uterine malignancies in China.

Inclusion criteria

  • Primary uterine malignancies.

Exclusion criteria

Exclusion Criteria:

  • Metastatic malignancies to uterine corpus
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Interventions

  • OtherFollow-up for death and recurrence

    All patients are followed up to determine definite date of diagnosis, recurrence and death.

05

What researchers measure

Primary outcomes

  1. Overall survival

    Survival duration from diagnosis to death

    Time frame: 5 years

  2. Progression-free survival

    Survival duration from last treatment after remission to recurrence

    Time frame: 5 years

06

Study locations

1 of 1 sites recruiting
  • Lei Li
    Beijing, China/Beiing 100000, China
    Recruiting
07

References and documents

Publications

  • Li L, Ma SQ, Tan XJ, Zhong S, Wu M. Pelvic Exenteration for Recurrent and Persistent Cervical Cancer. Chin Med J (Engl). 2018 Jul 5;131(13):1541-1548. doi: 10.4103/0366-6999.235111. PubMed 29941707 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03291275
Lead sponsor
Lei Li
Responsible party
Lei Li (Professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Sep 25, 2017
Start date
Sep 1, 2017
Primary completion
Sep 1, 2022 (estimated)
Completion
Sep 1, 2023 (estimated)
Last update
Feb 8, 2018

Study contacts

Lei Li, MD
Contact
lileigh@163.com
13911988831 ext. +86
Lei Li, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endometrial Neoplasms→

Other studies from this sponsor

Lei Li

Start the discussion